Humans Keeping Machines in Check

Mark Michalski, MD, Executive Director of the MGH/BWH Center for Clinical Data Science gets to see, touch or hear about much of what’s happening in artificial intelligence.

“Nearly all the machine learning algorithms that are being assessed, developed or even conceptualized are for radiologist augmentation as opposed to replacement,” he says, offering as examples algorithms that not only prioritize worklists and flag anatomical abnormalities but also calculate probability metrics for critical findings.

“As powerful as these tools are, they still must be checked by a human to get to the levels of confidence that we need,” he says. “That may not always be the case, but it is the case today. Radiologists will be guiding the development of these tools for the foreseeable future, and these tools are not for final diagnosis.”

Who else is engaged in AI? Pathology, radiation oncology, cardiology and neurology, he notes. “In fact, every ‘-ology’ is having this same discussion. It just so happens that radiology is once again at the forefront of a technology revolution.” 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.